epitope mapping at the C-terminus of NAT-1 of human origin
recommended for detection of NAT-1 of human origin, NAT-2 of mouse and rat origin and, to a lesser extent, NAT-1 and NAT-3 of mouse and rat origin by WB, IP, IF and ELISA; ; also reactive with additional species, including porcine
NAT-1/2 Background Information Arylamine N-acetyltransferases (NAT-1 and NAT-2) catalyze N- or O-acetylation of heterocyclic and arylamine substrates in the detoxification of a wide array of drugs. Certain alleles causing high levels of N-acetyltransferase activity have been associated with colon and urinary bladder cancers, as NATs also bioactivate several known carcinogens. Both NAT-1 and NAT-2 are cytoplasmic proteins and play an active role in the detoxification of many arylamine and hydrazine drugs. N-acetylation polymorphism is determined by the level of NAT activity in liver tissues, and has been linked to the action and toxicity of drugs that contain amines. Human NAT-1 is the functional homolog of rodent NAT-2, while human NAT-2 is the functional homolog of rodent NAT-1.
NAT-1/2 (C-16)
Click on image to enlarge
NAT-1/2 (C-16): sc-47219. Western blot analysis of NAT-1 expression in non-transfected: sc-117752 (A) and human NAT-1 transfected: sc-112994 (B) 293T whole cell lysates.
NAT-1/2 (C-16): sc-47219. Western blot analysis of NAT-1 expression in non-transfected: sc-117752 (A) and human NAT-1 transfected: sc-116170 (B) 293T whole cell lysates.
NAT-1/2 (C-16): sc-47219. Western blot analysis of NAT-2 expression in non-transfected: sc-117752 (A) and mouse NAT-2 transfected: sc-121945 (B) 293T whole cell lysates.
